Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Neil E Fleshner
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.
Urol Oncol. 2017 Aug 03;:
Testosterone Responders to Continuous Androgen Deprivation Therapy Exhibit Considerable Variations in Testosterone Levels on Follow-Up: Implications for Clinical Practice.
J Urol. 2017 Jul 24;:
Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series.
Urol Oncol. 2017 Jul 17;:
JAMA Intern Med. 2017 Jul 17;:
Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.
Oncol Lett. 2017 Jul;14(1):390-396
Psychological distress and lifestyle disruption in low risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy.
J Psychosoc Oncol. 2017 Jun 14;:0
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Eur Urol. 2017 May 13;:
Oncotarget. 2017 Apr 18;8(16):25928-25941
What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):118-122
Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.
Can Urol Assoc J. 2017 Jan-Feb;11(1-2):41-46
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto